Expression of partitioning defective 3 (Par-3) for predicting extrahepatic metastasis and survival with hepatocellular carcinoma

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 1684-1697

  Jan, Yee Jee ^a   Ko, Bor Sheng ^b,c   Liu, Tzu An ^b   Wu, Yao Ming ^c   Liang, Shu Man ^b   Chen, Shyh Chang ^a   Wang, John ^a   Liou, Jun Yang ^b,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Metastasis; Par 3; Survival

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 3; CELL CYCLE PROTEIN; MEMBRANE PROTEIN; PARD3 PROTEIN, HUMAN; PROTEIN 14 3 3;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; DISTANT METASTASIS; EXTRAHEPATIC METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; HEPG2 CELL LINE; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

14-3-3 PROTEINS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84878667715     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14011684     Document Type: Article

References (35)

1. Sherman, M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 2010, 30, 3-16.
2. Rampone, B.; Schiavone, B.; Martino, A.; Viviano, C.; Confuorto, G. Current management strategy of hepatocellular carcinoma. World J. Gastroenterol. 2009, 15, 3210-3216.
3. Natsuizaka, M.; Omura, T.; Akaike, T.; Kuwata, Y.; Yamazaki, K.; Sato, T.; Karino, Y.; Toyota, J.; Suga, T.; Asaka, M. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J. Gastroenterol. Hepatol. 2005, 20, 1781-1787.
4. Hasegawa, K.; Kokudo, N. Surgical treatment of hepatocellular carcinoma. Surg. Today 2009, 39, 833-843.
5. Sawada, N.; Murata, M.; Kikuchi, K.; Osanai, M.; Tobioka, H.; Kojima, T.; Chiba, H. Tight junctions and human diseases. Med. Electron Microsc. 2003, 36, 147-156.
6. Lin, D.; Edwards, A.S.; Fawcett, J.P.; Mbamalu, G.; Scott, J.D.; Pawson, T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat. Cell Biol. 2000, 2, 540-547.
7. Ooshio, T.; Fujita, N.; Yamada, A.; Sato, T.; Kitagawa, Y.; Okamoto, R.; Nakata, S.; Miki, A.; Irie, K.; Takai, Y. Cooperative roles of Par-3 and afadin in the formation of adherens and tight junctions. J. Cell Sci. 2007, 120, 2352-2365.
8. Chen, X.; Macara, I.G. Par-3 controls tight junction assembly through the Rac exchange factor Tiam1. Nat. Cell Biol. 2005, 7, 262-269.
9. Suzuki, A.; Ohno, S. The PAR-aPKC system: Lessons in polarity. J. Cell Sci. 2006, 119, 979-987.
10. Humbert, P.O.; Dow, L.E.; Russell, S.M. The Scribble and Par complexes in polarity and migration: friends or foes? Trends Cell Biol. 2006, 16, 622-630.
11. Hutterer, A.; Betschinger, J.; Petronczki, M.; Knoblich, J.A. Sequential roles of Cdc42, Par-6, aPKC, and Lgl in the establishment of epithelial polarity during Drosophila embryogenesis. Dev. Cell 2004, 6, 845-854.
12. Shin, K.; Fogg, V.C.; Margolis, B. Tight junctions and cell polarity. Annu. Rev. Cell Dev. Biol. 2006, 22, 207-235.
13. Ozdamar, B.; Bose, R.; Barrios-Rodiles, M.; Wang, H.R.; Zhang, Y.; Wrana, J.L. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307, 1603-1609.
14. Nolan, M.E.; Aranda, V.; Lee, S.; Lakshmi, B.; Basu, S.; Allred, D.C.; Muthuswamy, S.K. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res. 2008, 68, 8201-8209.
15. Eder, A.M.; Sui, X.; Rosen, D.G.; Nolden, L.K.; Cheng, K.W.; Lahad, J.P.; Kango-Singh, M.; Lu, K.H.; Warneke, C.L.; Atkinson, E.N.; et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 12519-12524.
16. Regala, R.P.; Weems, C.; Jamieson, L.; Copland, J.A.; Thompson, E.A.; Fields, A.P. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem. 2005, 280, 31109-31115.
17. Kunnev, D.; Ivanov, I.; Ionov, Y. Par-3 partitioning defective 3 homolog (C. elegans) and androgen-induced prostate proliferative shutoff associated protein genes are mutationally inactivated in prostate cancer cells. BMC Cancer 2009, 9, 318.
18. Zen, K.; Yasui, K.; Gen, Y.; Dohi, O.; Wakabayashi, N.; Mitsufuji, S.; Itoh, Y.; Zen, Y.; Nakanuma, Y.; Taniwaki, M.; et al. Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma. Oncogene 2009, 28, 2910-2918.
19. Zitzelsberger, H.; Hieber, L.; Richter, H.; Unger, K.; Briscoe, C.V.; Peddie, C.; Riches, A. Gene amplification of atypical PKC-binding PARD3 in radiation-transformed neoplastic retinal pigment epithelial cell lines. Genes Chromosomes Cancer 2004, 40, 55-59.
20. Fang, C.M.; Xu, Y.H. Down-Regulated expression of atypical PKC-binding domain deleted asip isoforms in human hepatocellular carcinomas. Cell Res. 2001, 11, 223-229.
21. Gao, L.; Macara, I.G.; Joberty, G. Multiple splice variants of Par3 and of a novel related gene, Par3L, produce proteins with different binding properties. Gene 2002, 294, 99-107.
22. Kohjima, M.; Noda, Y.; Takeya, R.; Saito, N.; Takeuchi, K.; Sumimoto, H. PAR3beta, a novel homologue of the cell polarity protein PAR3, localizes to tight junctions. Biochem. Biophys. Res. Commun. 2002, 299, 641-646.
23. Yoshii, T.; Mizuno, K.; Hirose, T.; Nakajima, A.; Sekihara, H.; Ohno, S. sPAR-3, a splicing variant of PAR-3, shows cellular localization and an expression pattern different from that of PAR-3 during enterocyte polarization. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288, G564-G570.
24. Wang, Y.; Du, D.; Fang, L.; Yang, G.; Zhang, C.; Zeng, R.; Ullrich, A.; Lottspeich, F.; Chen, Z. Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. EMBO J. 2006, 25, 5058-5070.
25. Wang, X.; Nie, J.; Zhou, Q.; Liu, W.; Zhu, F.; Chen, W.; Mao, H.; Luo, N.; Dong, X.; Yu, X. Downregulation of Par-3 expression and disruption of Par complex integrity by TGF-beta during the process of epithelial to mesenchymal transition in rat proximal epithelial cells. Biochim. Biophys. Acta 2008, 1782, 51-59.
26. Mishima, A.; Suzuki, A.; Enaka, M.; Hirose, T.; Mizuno, K.; Ohnishi, T.; Mohri, H.; Ishigatsubo, Y.; Ohno, S. Over-Expression of PAR-3 suppresses contact-mediated inhibition of cell migration in MDCK cells. Genes Cells 2002, 7, 581-596.
27. Izaki, T.; Kamakura, S.; Kohjima, M.; Sumimoto, H. Phosphorylation-Dependent binding of 14-3-3 to Par3beta, a human Par3-related cell polarity protein. Biochem. Biophys. Res. Commun. 2005, 329, 211-218.
28. Ko, B.S.; Chang, T.C.; Hsu, C.; Chen, Y.C.; Shen, T.L.; Chen, S.C.; Wang, J.; Wu, K.K.; Jan, Y.J.; Liou, J.Y. Overexpression of 14-3-3epsilon predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology 2011, 58, 705-711.
29. Ko, B.S.; Lai, I.R.; Chang, T.C.; Liu, T.A.; Chen, S.C.; Wang, J.; Jan, Y.J.; Liou, J.Y. Involvement of 14-3-3gamma overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum. Pathol. 2011, 42, 129-135.
30. Liu, T.A.; Jan, Y.J.; Ko, B.S.; Chen, S.C.; Liang, S.M.; Hung, Y.L.; Hsu, C.; Shen, T.L.; Lee, Y.M.; Chen, P.F.; et al. Increased expression of 14-3-3beta promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am. J. Pathol. 2011, 179, 2698-2708.
31. Llovet, J.M.; Bru, C.; Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 1999, 19, 329-338.
32. Barnes, D.M.; Harris, W.H.; Smith, P.; Millis, R.R.; Rubens, R.D. Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br. J. Cancer 1996, 74, 1445-1451.
33. Chang, G.C.; Liu, K.J.; Hsieh, C.L.; Hu, T.S.; Charoenfuprasert, S.; Liu, H.K.; Luh, K.T.; Hsu, L.H.; Wu, C.W.; Ting, C.C.; et al. Identification of alpha-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin. Cancer Res. 2006, 12, 5746-5754.
34. Jan, Y.J.; Ko, B.S.; Hsu, C.; Chang, T.C.; Chen, S.C.; Wang, J.; Liou, J.Y. Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum. Pathol. 2009, 40, 1384-1390.
35. Lai, I.R.; Chu, P.Y.; Lin, H.S.; Liou, J.Y.; Jan, Y.J.; Lee, J.C.; Shen, T.L. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am. J. Pathol. 2010, 177, 1629-1637.